The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...
Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...
Asianet Newsable on MSN
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India Tirzepatide is used to manage type 2 ...
On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...
Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...
US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...
Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...
In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...
Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...
The multiple 'large' orders of L&T include a contract with Hindalco for the construction of a 180 KTPA Aluminium Smelter ...
Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...
Stocks to watch today include Cipla, IndusInd, Wonderland Foods, Hero MotoCorp, Premier Energies, Welspun, Coal India, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback